UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 196

Sortiert nach

A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study

Osteoarthritis and cartilage, 2017-10, Vol.25 (10), p.1598-1606

2017

Link zum Volltext

Verfügbarkeit prüfen

Treating rheumatoid arthritis to target: recommendations of an international task force

Annals of the Rheumatic Diseases, 2010-04, Vol.69 (4), p.631-637

2010

Link zum Volltext

Verfügbarkeit prüfen

A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis

Osteoarthritis and cartilage, 2021-05, Vol.29 (5), p.654-666

2021

Link zum Volltext

Verfügbarkeit prüfen

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011

Annals of the rheumatic diseases, 2012-04, Vol.71 (Suppl 2), p.i2-i45

2012

Link zum Volltext

Verfügbarkeit prüfen

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009

Annals of the rheumatic diseases, 2010-01, Vol.69 (Suppl 1), p.i2-i29

2010

Link zum Volltext

Verfügbarkeit prüfen

A Phase 3 study of lower-dose diclofenac submicron particle capsules demonstrates effective pain relief in patients with osteoarthritis

Osteoarthritis and cartilage, 2013-04, Vol.21, p.S267-S267

2013

Link zum Volltext

Verfügbarkeit prüfen

THU0336 Lower-Dose Solumatrix® Indomethacin Efficacy in Acute Pain: Results from Two Phase 3 Studies

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.298-298

2014

Link zum Volltext

Verfügbarkeit prüfen

THU0337 Lower-Dose Solumatrix® Indomethacin: Combined Safety Data from Two Phase 3 Studies in Patients with Acute Pain following Elective Surgery

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.298

2014

Link zum Volltext

Verfügbarkeit prüfen

SAT0139 Analysis of Outcomes After Non-Medical Switching of Anti–Tumor Necrosis Factor Agents

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.701-701

2015

Link zum Volltext

Verfügbarkeit prüfen

Solumatrix diclofenac safety in older patients with osteoarthritis pain

Osteoarthritis and cartilage, 2015-04, Vol.23, p.A335-A336

2015

Link zum Volltext

Verfügbarkeit prüfen

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

Annals of the rheumatic diseases, 2011-03, Vol.70 (Suppl 1), p.i2-i36

2011

Link zum Volltext

Verfügbarkeit prüfen

Morning stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisone

Scandinavian journal of rheumatology, 2015-09, Vol.44 (5), p.354-358

2015

Link zum Volltext

Verfügbarkeit prüfen

Low-dose solumatrix meloxicam demonstrates low systemic exposure and efficacy in patients with osteoarthitis pain in clinical studies

Osteoarthritis and cartilage, 2015-04, Vol.23, p.A324-A325

2015

Link zum Volltext

Verfügbarkeit prüfen

Low-dose SoluMatrix meloxicam results in clinically meaningful improvements in pain in a phase 3 study of patients with osteoarthritis

Osteoarthritis and cartilage, 2016-04, Vol.24, p.S419-S420

2016

Link zum Volltext

Verfügbarkeit prüfen

Solumatrix meloxicam safety in older patients with osteoarthritis pain

Osteoarthritis and cartilage, 2016-04, Vol.24, p.S188-S188

2016

Link zum Volltext

Verfügbarkeit prüfen

THU0126 Dose Titration of Biologics for The Treatment of Rheumatoid Arthritis and Ankylosing Spondylitis: A Systematic Literature Review

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.225

2016

Link zum Volltext

Verfügbarkeit prüfen

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008

Annals of the rheumatic diseases, 2008-12, Vol.67 (Suppl 3), p.iii2-iii25

2008

Link zum Volltext

Verfügbarkeit prüfen

(380) A novel application of the Medication Event Monitoring System (MEMS) to track rescue medication use in a phase 3 study of low-dose SoluMatrix meloxicam in patients with osteoarthritis (OA) pain

The journal of pain, 2016-04, Vol.17 (4), p.S70-S70

2016

Link zum Volltext

Verfügbarkeit prüfen

THU0200 Lower-Dose Solumatrix® Meloxicam: Efficacy and Safety in A Phase 3 Study in Adults with Osteoarthritis Pain

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.250-251

2014

Link zum Volltext

Verfügbarkeit prüfen

Diclofenac submicron particle capsules demonstrate early and sustained acute pain relief in a phase 3 study in patients following bunionectomy surgery

Osteoarthritis and cartilage, 2013-04, Vol.21, p.S291-S291

2013

Link zum Volltext

Verfügbarkeit prüfen

SAT0428 Safety, Clinical and Imaging Outcomes of A Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in The Treatment of Osteoarthritis of The Knee: Exploratory Analysis of Results from A 24 Week, Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.826-826

2016

Link zum Volltext

Verfügbarkeit prüfen

SAT0640-HPR Understanding The Importance of A Patient's Role in The Management of RA: Physician- and Patient-Based Survey Results Developed by The RA Narrative Advisory Panel

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.1295-1295

2016

Link zum Volltext

Verfügbarkeit prüfen

Outcome measures in placebo-controlled trials of osteoarthritis: responsiveness to treatment effects in the REPORT database

Osteoarthritis and cartilage, 2011-05, Vol.19 (5), p.483-492

2011

Link zum Volltext

Verfügbarkeit prüfen

(402) Indomethacin submicron particle capsules: reduced opioid rescue medication usage in a phase 3 study in patients with acute pain after elective surgery

The journal of pain, 2014-04, Vol.15 (4), p.S76-S76

2014

Link zum Volltext

Verfügbarkeit prüfen

Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis

Annals of the rheumatic diseases, 2004-08, Vol.63 (8), p.931-939

2004

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 196

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(162)
Mit Volltextzugriff
(153)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(196)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

Humans
(120)
Science & Technology
(101)
Life Sciences & Biomedicine
(99)
Rheumatology
(66)
Female
(43)
Male
(39)
Biological And Medical Sciences
(31)
Medical Sciences
(30)
Adult
(27)
Middle Aged
(27)
Arthritis, Rheumatoid - Drug Therapy
(24)
Antirheumatic Agents - Therapeutic Use
(23)
United States
(22)
Rheumatoid Arthritis
(21)
General & Internal Medicine
(20)
Medicine, General & Internal
(20)
Treatment Outcome
(20)
Aged
(18)
Diseases Of The Osteoarticular System
(18)
Immunology
(15)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study

Treating rheumatoid arthritis to target: recommendations of an international task force

A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009

A Phase 3 study of lower-dose diclofenac submicron particle capsules demonstrates effective pain relief in patients with osteoarthritis

THU0336 Lower-Dose Solumatrix® Indomethacin Efficacy in Acute Pain: Results from Two Phase 3 Studies

THU0337 Lower-Dose Solumatrix® Indomethacin: Combined Safety Data from Two Phase 3 Studies in Patients with Acute Pain following Elective Surgery

SAT0139 Analysis of Outcomes After Non-Medical Switching of Anti–Tumor Necrosis Factor Agents

Solumatrix diclofenac safety in older patients with osteoarthritis pain

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

Morning stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisone

Low-dose solumatrix meloxicam demonstrates low systemic exposure and efficacy in patients with osteoarthitis pain in clinical studies

Low-dose SoluMatrix meloxicam results in clinically meaningful improvements in pain in a phase 3 study of patients with osteoarthritis

Solumatrix meloxicam safety in older patients with osteoarthritis pain

THU0126 Dose Titration of Biologics for The Treatment of Rheumatoid Arthritis and Ankylosing Spondylitis: A Systematic Literature Review

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008

(380) A novel application of the Medication Event Monitoring System (MEMS) to track rescue medication use in a phase 3 study of low-dose SoluMatrix meloxicam in patients with osteoarthritis (OA) pain

THU0200 Lower-Dose Solumatrix® Meloxicam: Efficacy and Safety in A Phase 3 Study in Adults with Osteoarthritis Pain

Diclofenac submicron particle capsules demonstrate early and sustained acute pain relief in a phase 3 study in patients following bunionectomy surgery

SAT0428 Safety, Clinical and Imaging Outcomes of A Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in The Treatment of Osteoarthritis of The Knee: Exploratory Analysis of Results from A 24 Week, Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

SAT0640-HPR Understanding The Importance of A Patient's Role in The Management of RA: Physician- and Patient-Based Survey Results Developed by The RA Narrative Advisory Panel

Outcome measures in placebo-controlled trials of osteoarthritis: responsiveness to treatment effects in the REPORT database

(402) Indomethacin submicron particle capsules: reduced opioid rescue medication usage in a phase 3 study in patients with acute pain after elective surgery

Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis

Suchergebnisse filtern